Phathom Pharmaceuticals ( (PHAT) ) has shared an update.
Phathom Pharmaceuticals has appointed Theodore R. Schroeder to its Board of Directors as a Class I director, effective April 16, 2025. Mr. Schroeder, with over 30 years of experience in drug development and commercialization, will serve on the audit committee and brings significant leadership experience from his previous roles at various pharmaceutical companies. His appointment is expected to strengthen the board with his extensive industry knowledge and leadership skills.
Spark’s Take on PHAT Stock
According to Spark, TipRanks’ AI Analyst, PHAT is a Neutral.
Phathom Pharmaceuticals’ stock is characterized by significant revenue growth potential but is hampered by financial instability and reliance on external funding. Despite strong market positioning for VOQUEZNA, financial risks and market challenges are notable. Technical indicators reveal a cautious sentiment, while valuation remains unattractive due to negative profitability. The overall score reflects these mixed signals.
To see Spark’s full report on PHAT stock, click here.
More about Phathom Pharmaceuticals
YTD Price Performance: -34.92%
Average Trading Volume: 1,215,288
Technical Sentiment Signal: Buy
Current Market Cap: $322.4M
See more data about PHAT stock on TipRanks’ Stock Analysis page.